TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
RI-South Korea joint venture establishes $30 million oncology factory
PT CKD OTTO Pharmaceuticals, with a production capacity of 1.6 million vials per year, plans to sell 50 percent of its products on the global market given that the production facilities at the factory met European Good Manufacturing Practice (EU-GMP) requirements and obtained halal certification.
Change Size
CKD OTTO Pharmaceuticals inaugurated the opening its new factory in Cikarang, Bekasi, West Java on Tuesday, July 9, 2019. The factory produces cancer-treatment pharmaceutical products, better known as oncology products (Shutterstock/Aleksandar Karanov)
P
T CKD OTTO Pharmaceuticals (CKD OTTO Pharma) has recently established a US$30 million factory to produce cancer treatment pharmaceutical products, better known as oncology products.
President director Baik In Hyun said at the grand opening of the factory on Tuesday that the company had obtained legal distribution permits (NIE) to market its new powder and liquid injection oncology products.
CKD OTTO Pharma is a joint venture between Korean pharmaceutical company Chong Kun Dang Pharmaceutical Corp. (CKD) and PT OTTO Pharmaceutical Industries (OTTO), a subsidiary of the Indonesian pharmaceutical MENSA Group.
“The products consist of gemcitabine, paclitaxel and oxaliplatin,” Baik said, adding that besides producing the three, the company also produced seven other products - docetaxel, epirubicin, carboplatin, doxorubocin, methotrexatee, pemetrexed and bortezomib.
The company was processing permits for the distribution of the other seven, he added.
He said that the company, with a total production capacity of 1.6 million vials per year, was targeting to sell 50 percent of its products on the global market given that the production facilities at the factory met European Good Manufacturing Practice (EU-GMP) requirements and obtained halal certification.
“For the global market, we are targeting to export our oncology products to countries in the Middle East, North Africa, Europe and Southeast Asia,” he said. “We are also targeting to control a 30-percent share of the domestic market by 2024.”
